Brittle type 1 diabetes mellitus.
A small group of patients affected by type 1 diabetes mellitus is characterized by a severe instability of glycemic values with frequent and unpredictable hypoglycemic and/or ketoacidosis episodes which cannot be explained by errors of patients or diabetologists. The quality of life of these patients is dramatically compromised in particular because of the frequency of acute events, hospital recoveries and precocious appearance of chronic complications. This clinical condition has been defined as "brittle diabetes". A precise quantification of these patients is difficult because diagnostic criteria are still not well defined and it is often difficult to verify errors of patients in terms of inappropriate conduct with the pathology. Even more than the other kinds of diabetes, therapy is based on education, glycemic control, intensive therapy and strict interaction between physicians and patients. The introduction of insulin analogous, with either ultra-fast and ultra-slow action and the use of subcutaneous insulin pumps have significantly increased the possibility of treating the most of these cases. However, there is a minority of patients resistant to the therapy. In similar cases, pancreas or islet transplantation represents an effective therapeutic option entailing good expected outcomes. The main limiting factor of beta cell function replacement by transplantation is so far represented by the potentially severe side effects of the immunosuppression therapy necessary to avoid graft rejection and recurrence of autoimmunity.
Bertuzzi
Federico
F
Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Palermo, Italy. fbertuzzi@ismett.edu
Verzaro
Roberto
R
Provenzano
Vincenzo
V
Ricordi
Camillo
C
D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy*; D016883:Diabetic Ketoacidosis / Q000150:complications; D003937:Diagnosis, Differential; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D050417:Insulin-Secreting Cells / Q000378:metabolism; D016381:Islets of Langerhans Transplantation / Q000379:methods; D016035:Pancreas Transplantation / Q000379:methods; D016896:Treatment Outcome
D001786:Blood Glucose; D007166:Immunosuppressive Agents; D007328:Insulin